Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 21 03 2021
revised: 17 06 2021
accepted: 24 06 2021
pubmed: 8 8 2021
medline: 21 9 2021
entrez: 7 8 2021
Statut: ppublish

Résumé

The short- and long-term implications of identifying totally occluded culprit coronary arteries (TOCCA) in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) have not been well studied. This study compares clinical characteristics, short- and long-term outcomes of patients with NSTEMI identified with TOCCA to that of patients with non-TOCCA undergoing percutaneous coronary intervention (PCI). We analyzed data from patients with NSTEMI undergoing single-vessel PCI within the Melbourne Interventional Group multi-center registry between 2005 and 2017. Those with TOCCA were compared to those with non-TOCCA. The primary endpoint was 30-day major adverse cardiac events (MACE). Secondary endpoints included 12-month MACE and long-term mortality. A total of 6,829 patients with NSTEMI had single-vessel PCI of which 954 (14%) had TOCCA. Most TOCCA were non-left anterior descending (right coronary artery 39% versus circumflex 33% versus left anterior descending 26%; p <0.001). Cardiogenic shock and left ventricular dysfunction were higher in the TOCCA group, but non-TOCCA patients had more baseline comorbidities. Thirty-day MACE was higher in the TOCCA group (6.7% versus 3.8%; p <0.001). Long-term mortality with an average follow-up of 4.9 years was higher in the non-TOCCA group (12% versus 18%, p <0.01). Multivariable Cox-proportional hazards regression identified TOCCA as an independent predictor of 30-day MACE (HR = 1.93; 95%CI: 1.4-2.6), but not long-term mortality, which was predicted by baseline comorbidities. In conclusion, while patients with NSTEMI with TOCCA undergoing PCI represent a more unstable subgroup early on, long-term outcomes appear more dependent on baseline comorbidities.

Identifiants

pubmed: 34362552
pii: S0002-9149(21)00628-7
doi: 10.1016/j.amjcard.2021.06.043
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-57

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Himawan Fernando (H)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia.

Stephen J Duffy (SJ)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Centre of Cardiovascular Research and Education in Therapeutics (CCRE), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Ashlea Low (A)

Department of Cardiology, Ballarat Health Services, Ballarat, Victoria, Australia.

Diem Dinh (D)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Nick Adrianopoulos (N)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Anand Sharma (A)

Department of Cardiology, Ballarat Health Services, Ballarat, Victoria, Australia.

Karlheinz Peter (K)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.

Dion Stub (D)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.

Kai'En Leong (K)

Department of Cardiology, Ballarat Health Services, Ballarat, Victoria, Australia.

Andrew Ajani (A)

Department of Cardiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

David Clark (D)

Department of Cardiology Austin Health, Melbourne, Victoria, Australia.

Melanie Freeman (M)

Department of Cardiology, Box Hill Hospital, Melbourne, Victoria, Australia.

Martin Sebastian (M)

Department of Cardiology, Barwon Health, Geelong, Victoria, Australia.

Angela Brennan (A)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Laura Selkrig (L)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Christopher M Reid (CM)

School of Public Health, Curtin University, Perth, Western Australia, Australia.

David Kaye (D)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.

Ernesto Oqueli (E)

Department of Cardiology, Ballarat Health Services, Ballarat, Victoria, Australia; School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia. Electronic address: Ernesto.OqueliFlores@bhs.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH